Adaptin Bio (APTN) Liabilities and Shareholders Equity (2022 - 2026)

Adaptin Bio's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $706117.0 for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 75.26% year-over-year to $706117.0; the TTM figure through Mar 2026 stood at $4.0 million (up 28.23% YoY), while the FY2025 annual figure was $619159.0, up 158.61% from the prior year.
• Liabilities and Shareholders Equity came in at $706117.0 for Q1 2026 at Adaptin Bio, up from $619159.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 million in Q1 2025 to a low of $322.0 in Q2 2024.
• A 5-year average of $588590.7 and a median of $119957.5 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 750953.68% in 2025 and sank 75.26% in 2026, its largest moves.
• Adaptin Bio's Liabilities and Shareholders Equity stood at $500.0 in 2022, then slipped by 24.0% to $380.0 in 2023, then soared by 62903.95% to $239415.0 in 2024, then jumped by 158.61% to $619159.0 in 2025, then grew by 14.04% to $706117.0 in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $706117.0, $619159.0, and $979474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison